WO2001015655A3 - Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders - Google Patents

Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders Download PDF

Info

Publication number
WO2001015655A3
WO2001015655A3 PCT/IL2000/000509 IL0000509W WO0115655A3 WO 2001015655 A3 WO2001015655 A3 WO 2001015655A3 IL 0000509 W IL0000509 W IL 0000509W WO 0115655 A3 WO0115655 A3 WO 0115655A3
Authority
WO
WIPO (PCT)
Prior art keywords
existence
diagnosing
peptides
substances
methods
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IL2000/000509
Other languages
French (fr)
Other versions
WO2001015655A2 (en
Inventor
Daniel M Michaelson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ramot at Tel Aviv University Ltd
Original Assignee
Ramot at Tel Aviv University Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot at Tel Aviv University Ltd filed Critical Ramot at Tel Aviv University Ltd
Priority to EP00954874A priority Critical patent/EP1209969A2/en
Priority to AU67223/00A priority patent/AU6722300A/en
Publication of WO2001015655A2 publication Critical patent/WO2001015655A2/en
Priority to US09/847,586 priority patent/US20030148404A1/en
Publication of WO2001015655A3 publication Critical patent/WO2001015655A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Neurosurgery (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A method of identifying an existence, non-existence, type or state of a neurodegenerative disorder in an individual. The method is effected by (a) immunoreacting with a serum sample derived from the individual at least one peptide representing at least one epitope derived from an endogenous protein to which at least one antibody is produced in vivo at onset or during progression of the neurodegenerative disorder, the at least one peptide being selected such that the at least one antibody being capable of immunobinding with the at least one peptide; and (b) detecting a presence, absence or degree of the immunobinding to thereby identify the existence, non-existence, type or state of the neurodegenerative disorder.
PCT/IL2000/000509 1999-08-31 2000-08-27 Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders Ceased WO2001015655A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP00954874A EP1209969A2 (en) 1999-08-31 2000-08-27 Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
AU67223/00A AU6722300A (en) 1999-08-31 2000-08-27 Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
US09/847,586 US20030148404A1 (en) 2000-07-27 2001-05-03 Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38634799A 1999-08-31 1999-08-31
US09/386,347 1999-08-31
US22115000P 2000-07-27 2000-07-27
US60/221,150 2000-07-27

Publications (2)

Publication Number Publication Date
WO2001015655A2 WO2001015655A2 (en) 2001-03-08
WO2001015655A3 true WO2001015655A3 (en) 2001-11-22

Family

ID=26915543

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2000/000509 Ceased WO2001015655A2 (en) 1999-08-31 2000-08-27 Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders

Country Status (3)

Country Link
EP (1) EP1209969A2 (en)
AU (1) AU6722300A (en)
WO (1) WO2001015655A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU784568B2 (en) * 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
JP2004530879A (en) * 2001-05-03 2004-10-07 シグマ−ジェノシス リミテッド How to build a protein microarray
AR038568A1 (en) 2002-02-20 2005-01-19 Hoffmann La Roche ANTI-A BETA ANTIBODIES AND ITS USE
GB0314943D0 (en) * 2003-06-25 2003-07-30 Proteome Sciences Plc Screening methods
MY155286A (en) 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541294A (en) * 1992-05-28 1996-07-30 New York Blood Center, Inc. Removal of antibodies from blood-derived compositions while retaining coagulation factors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541294A (en) * 1992-05-28 1996-07-30 New York Blood Center, Inc. Removal of antibodies from blood-derived compositions while retaining coagulation factors

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
ELIZAN T.S. ET AL.: "Antineurofilament antibodies in postencephalitic and idiopathic Parkinson's disease", J. OF NEUROL. SCI., vol. 59, 1983, pages 341 - 347, XP002943983 *
GRUNDKE-IQBAL I. ET AL.: "Microtubule-associated polypeptides tau are altered in Alzheimer paired helical filaments", MOLECULAR BR. RES., vol. 4, 1988, pages 43 - 52, XP002943977 *
HASSIN-BAER S. ET AL.: "Antibodies from Down's syndrome patients bind to the same cholinergic neurofilament protein recognized by Alzheimer's disease antibodies", NEUROLOGY, vol. 42, 1992, pages 551 - 555, XP002943980 *
KUMAR M. ET AL.: "Serum IgG brain reactive antibodies in Alzheimer disease and down syndrome", ALZ. DIS. & ASSOC. DISORD., vol. 2, no. 1, 1988, pages 50 - 55, XP002943979 *
LOPEZ O.L. ET AL.: "Serum auto-antibodies in Alzheimer's disease", ACTA NEUROL. SCAND., vol. 84, 1991, pages 441 - 444, XP002943984 *
MICHAELSON D.M. ET AL.: "Serum antibodies to cholinergic neurons in Alzheimer's disease", PROG. IN CLIN. & BIOL. RES., vol. 317, 1989, pages 689 - 694, XP002943982 *
MICHAELSON D.M.: "Decreased density of forebrain cholinergic neurons and disintegration of the spatial organization of behavior in experimental autoimmune demientia (EAD)", ANN. NY ACAD. SCI., vol. 695, 1993, pages 244 - 248, XP002943985 *
ORON L. ET AL.: "Animal model and in vitro studies of anti-neurofilament antibodies mediated neurodegeneration in Alzheimer's disease", J. NEURAL TRANSM., vol. 49, 1997, pages 77 - 84, XP002943978 *
SALIH A.M. ET AL.: "Prevalence of antibodies to neurofilament polypeptides in patients with rheumatoid arthritis complicated by peripheral neuropathy", CLIN. & EXP. RHEUMAT., vol. 16, 1998, pages 689 - 694, XP002943976 *
SOUSSAN L. ET AL.: "Antibodies to different isoforms of the heavy neurofilament protein (NF-H) in normal aging and Alzheimer's disease", MOL. NEUROBIOL., vol. 9, no. 1-3, 1994, pages 83 - 91, XP002943981 *

Also Published As

Publication number Publication date
EP1209969A2 (en) 2002-06-05
AU6722300A (en) 2001-03-26
WO2001015655A2 (en) 2001-03-08

Similar Documents

Publication Publication Date Title
Roubey Autoantibodies to phospholipid-binding plasma proteins: a new view of lupus anticoagulants and other “antiphospholipid” autoantibodies
WO1999024463A3 (en) Signal peptide-containing proteins
EP2172486A3 (en) Monoclonal antibody against a prion protein and its use for the detection of prions
EP1320754B8 (en) Detection of peptides
DK0557350T3 (en) Assay for glycated blood proteins
DE60011390D1 (en) METHOD AND DEVICE FOR IDENTIFYING OR CARACTERIZING POLYPEPTIDES
AU7652194A (en) A method of assaying collagen fragments in body fluids, a test kit and means for carrying out the method and use of the method to diagnose the presence of disorders associated with the metabolism of collagen
AU2003280753A1 (en) Kit for assaying human low-molecular weight cd14 and antibody
EP2048505A3 (en) Method for early recognition of the seroconversion of an antibody to hepatitis C
SE9604815D0 (en) A method or diagnosis
AU2002223044A1 (en) Kit and method for detecting the esm-1 protein
WO1996021734A3 (en) P15 and tyrosinase melanoma antigens and their use in diagnostic and therapeutic methods
WO2000035950A3 (en) Reagents and methods useful for detecting diseases of the breast
WO2002004949A3 (en) Reagents and methods for identification of binding agents
ZA976196B (en) Peptide reagent for the detection of human cytomegalovirus (cmv)
WO2001015655A3 (en) Peptides and substances, methods and devices using same for diagnosing and treating neurodegenerative disorders
ATE389881T1 (en) DETECTION OF SMALL MOLECULES WITH PIEZO-ELECTRIC SENSOR
AU5479396A (en) Epstein-Barr virus peptides and antibodies against these peptides
WO2000007024A3 (en) Method of protein analysis
EP0331514A3 (en) Assaying the duchenne muscular dystrophy protein deletion or defect
AU6999296A (en) Assay for the diagnosis of dementia
DE3850650D1 (en) IMMUNITY TEST PROCEDURE AND REAGENT SET.
DE69817338D1 (en) METHOD FOR DETECTING AUTOIMMUN PATHOLOGIES
SE9602234D0 (en) A novel diagnostic method utilizing ECP, and reagents to be used in the methods
AU6189486A (en) Monoclonal antibodies to prosomal proteins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 519869

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000954874

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000954874

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000954874

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP